Deciphera Pharmaceuticals, Inc. (Nasdaq:DCPH), a clinical-stage
biopharmaceutical company addressing key mechanisms of tumor drug
resistance, today announced that data from four of the Company’s
pipeline programs will be presented in poster sessions at the
AACR-NCI-EORTC International Conference on Molecular Targets and
Cancer Therapeutics to be held October 26-30, 2019 in Boston,
MA.
A copy of each abstract will be available via the AACR-NCI-EORTC
International Conference on Molecular Targets and Cancer
Therapeutics website.
Details of the four poster sessions are as follows.
Poster Title: Phase 1b/2 study of rebastinib (DCC-2036)
in combination with paclitaxel: preliminary safety, efficacy,
pharmacokinetics and pharmacodynamics in patients with advanced or
metastatic solid tumors Session Title: Immune Modulators
Author: Filip Janku, MD, University of Texas MD Anderson
Cancer Center Session Date and Time: Monday, October 28,
12:30-4:00 PM ET Location: Hall D, Hynes Convention Center
Abstract Number: B055
Poster Title: Preclinical studies with DCC-3116, an ULK
kinase inhibitor designed to inhibit autophagy as a potential
strategy to address mutant RAS cancers Session Title: New
Molecular Targets Author: Bryan D. Smith, PhD, Deciphera
Pharmaceuticals Session Date and Time: Monday, October 28,
12:30-4:00 PM ET Location: Hall D, Hynes Convention Center
Abstract Number: B129
Poster Title: Updated results of phase 1 study of
ripretinib (DCC-2618), a broad-spectrum KIT and PDGFRA inhibitor,
in patients with gastrointestinal stromal tumor (GIST) by line of
therapy (NCT02571036) Session Title: Therapeutic Agents:
Small Molecule Kinase Inhibitors Author: Ping Chi, MD, PhD,
Memorial Sloan Kettering Cancer Center Session Date and
Time: Tuesday, October 29, 12:30-4:00 PM ET Location:
Hall D, Hynes Convention Center Abstract Number: C077
Poster Title: Phase 1 study of DCC-3014, an oral
inhibitor of CSF1R, to assess the safety, tolerability,
pharmacokinetics, and pharmacodynamics in patients with advanced
solid tumors, including diffuse-type tenosynovial giant cell tumor
Session Title: Therapeutic Agents: Small Molecule Kinase
Inhibitors Author: Matthew H. Taylor, MD, Oregon Health
& Science University Session Date and Time: Tuesday,
October 29, 12:30-4:00 PM ET Location: Hall D, Hynes
Convention Center Abstract Number: C087
About Ripretinib
Ripretinib is an investigational tyrosine kinase switch control
inhibitor that was engineered to broadly inhibit KIT and PDGFRα
mutated kinases by using a unique dual mechanism of action that
regulates the kinase switch pocket and activation loop. Ripretinib
is currently in clinical development for the treatment of KIT
and/or PDGFRα-driven cancers, including gastrointestinal stromal
tumors, or GIST, systemic mastocytosis, or SM, and other cancers.
Ripretinib inhibits initiating and secondary KIT mutations in exons
9, 11, 13, 14, 17, and 18, involved in GIST, as well as the primary
D816V exon 17 mutation involved in SM. Ripretinib also inhibits
primary PDGFRα mutations in exons 12, 14 and 18, including the exon
18 D842V mutation, involved in a subset of GIST. In June 2019, the
U.S. FDA granted Fast Track Designation to ripretinib for the
treatment of patients with advanced GIST who have received prior
treatment with imatinib, sunitinib and regorafenib.
Deciphera Pharmaceuticals has an exclusive license agreement
with Zai Lab (Shanghai) Co., Ltd. for the development and
commercialization of ripretinib in Greater China (Mainland China,
Hong Kong, Macau and Taiwan). Deciphera Pharmaceuticals retains
development and commercial rights for ripretinib in the rest of the
world.
About Rebastinib
Rebastinib is an investigational, orally administered, potent
and selective inhibitor of the TIE2 kinase, the receptor for
angiopoietins, an important family of vascular growth factors in
the tumor microenvironment that also activate pro-tumoral TIE2
expressing macrophages. In a Phase 1 clinical study, biomarker data
have demonstrated rebastinib-induced increases in the TIE2 ligand
angiopoietin 2, secondary to TIE2 inhibition. Rebastinib is
currently being evaluated in a Phase 1b/2 clinical study in
combination with paclitaxel (NCT03601897), in a Phase 1b/2 clinical
study in combination with carboplatin (NCT03717415), and in an
investigator sponsored Phase 1b trial in patients with metastatic
breast cancer in combination with paclitaxel or eribulin
(NCT02824575).
About DCC-3014
DCC-3014 is an investigational, orally administered, potent and
highly selective inhibitor of CSF1R. DCC-3014 was designed using
the Company’s proprietary switch control kinase inhibitor platform
to selectively bind to the CSF1R switch pocket. DCC-3014 has
greater than 100-fold selectivity for CSF1R over other closely
related kinases and has an even greater selectivity for CSF1R over
approximately 300 other human kinases. CSF1R controls the
differentiation and function of macrophages including Tumor
Associated Macrophages (TAMs) whose density within certain tumors
including cancers of the breast, cervix, pancreas, bladder and
brain correlates with poor prognosis. Tumors induce TAMs to
suppress a natural immune response mediated by cytotoxic T-cells, a
type of lymphocyte that would otherwise eradicate the tumor; a
process known as macrophage checkpoints. Through inhibition of
CSF1R, DCC-3014 has in preclinical studies demonstrated potent
macrophage checkpoint inhibition as both a single agent and in
combination with PD1 inhibitors and other T-cell checkpoint
inhibitors. DCC-3014 is currently being evaluated in a Phase 1
clinical study. For more information about the clinical trial
design please visit www.clinicaltrials.gov (NCT03069469).
About DCC-3116
DCC-3116 is a potential first-in-class small molecule designed
to inhibit cancer autophagy, a key tumor survival mechanism, by
inhibiting the ULK kinase. Subject to favorable investigational new
drug (IND)-enabling studies and filing and activation of an IND,
expected in mid-2020, Deciphera intends to develop DCC-3116 for the
potential treatment of mutant RAS cancers in combination with
inhibitors of downstream RAS effector targets including RAF, MEK,
or ERK inhibitors as well as with direct inhibitors of mutant
RAS.
About Deciphera Pharmaceuticals
Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical
company focused on improving the lives of cancer patients by
addressing key mechanisms of drug resistance that limit the rate
and/or durability of response to existing cancer therapies. Our
small molecule drug candidates are directed against an important
family of enzymes called kinases, known to be directly involved in
the growth and spread of many cancers. We use our deep
understanding of kinase biology together with a proprietary
chemistry library to purposefully design compounds that maintain
kinases in a “switched off” or inactivated conformation. These
investigational therapies comprise tumor-targeted agents designed
to address therapeutic resistance causing mutations and
immuno-targeted agents designed to control the activation of
immunokinases that suppress critical immune system regulators, such
as macrophages. We have used our platform to develop a diverse
pipeline of tumor-targeted and immuno-targeted drug candidates
designed to improve outcomes for patients with cancer by improving
the quality, rate and/or durability of their responses to
treatment.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, as amended, including, without limitation, statements
regarding our expectations regarding presenting additional data
from our Phase 1b/2 study of rebastinib in combination with
paclitaxel, preclinical studies with DCC-3116, updated results of
Phase 1 study of ripretinib in patients with GIST and Phase 1 study
of DCC-3014 in patients with advanced solid tumors, including
diffuse-type tenosynovial giant cell tumor, at an upcoming medical
meeting, and the timing of the potential filing of an IND for our
DCC-3116 candidate, subject to favorable IND enabling studies. The
words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,”
“anticipate,” “intend,” “believe,” “estimate,” “predict,”
“project,” “potential,” “continue,” “target” and similar
expressions are intended to identify forward-looking statements,
although not all forward-looking statements contain these
identifying words. Any forward-looking statements in this press
release are based on management’s current expectations and beliefs
and are subject to a number of risks, uncertainties and important
factors that may cause actual events or results to differ
materially from those expressed or implied by any forward-looking
statements contained in this press release, including, without
limitation, risks and uncertainties related to the delay of any
current or planned clinical studies or the development of our drug
candidates, including ripretinib, our ability to successfully
demonstrate the efficacy and safety of our drug candidates
including in later-stage studies, the preclinical and clinical
results for our drug candidates, which may not support further
development of such drug candidates, actions of regulatory
agencies, any or all of which may affect the initiation, timing and
progress of clinical studies and regulatory development and other
risks identified in our SEC filings, including our Quarterly Report
on Form 10-Q for the quarter ended June 30, 2019, and subsequent
filings with the SEC. We caution you not to place undue reliance on
any forward-looking statements, which speak only as of the date
they are made. We disclaim any obligation to publicly update or
revise any such statements to reflect any change in expectations or
in events, conditions or circumstances on which any such statements
may be based, or that may affect the likelihood that actual results
will differ from those set forth in the forward-looking statements.
Any forward-looking statements contained in this press release
represent our views only as of the date hereof and should not be
relied upon as representing its views as of any subsequent date. We
explicitly disclaim any obligation to update any forward-looking
statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191016005899/en/
Investor Relations: Jen Robinson Deciphera Pharmaceuticals, Inc.
jrobinson@deciphera.com 781-906-1112
Media: David Rosen Argot Partners David.Rosen@argotpartners.com
212-600-1902
Deciphera Pharmaceuticals (NASDAQ:DCPH)
Historical Stock Chart
From Aug 2024 to Sep 2024
Deciphera Pharmaceuticals (NASDAQ:DCPH)
Historical Stock Chart
From Sep 2023 to Sep 2024